SCP
VRTX icon

Syntal Capital Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Syntal Capital Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6,545
Closed -$1.71M – 119
2022
Q1 		$1.71M Buy
+6,545
New +$1.55M 0.67% 35
2020
Q3 		– Sell
-4,628
Closed -$1.34M – 126
2020
Q2 		$1.34M Buy
+4,628
New +$1.25M 0.63% 50

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Syntal Capital Partners's VRTX Position: Q2 2022 in Review

Syntal Capital Partners sold out of Vertex Pharmaceuticals (VRTX) in Q2 2022, closing a stake of 6,545 shares — an estimated $1.71M sold.

Syntal Capital Partners first reported a position in VRTX in Q2 2020 and held it in 2 quarters. The position peaked at $1.71M in Q1 2022. 1,106 funds tracked by Wall St. Rank hold VRTX as of Q2 2022.

  • Syntal Capital Partners reported no remaining Vertex Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Syntal Capital Partners sold 6,545 Vertex Pharmaceuticals shares in Q2 2022, an estimated $1.71M.
  • Syntal Capital Partners first reported a position in Vertex Pharmaceuticals in Q2 2020 and held it in 2 quarters.
  • Syntal Capital Partners's Vertex Pharmaceuticals position peaked at $1.71M in Q1 2022.
  • 1,106 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2022.

Based on Syntal Capital Partners's 13F filing for Q2 2022, filed 15 Aug 2022.